Clinical Trial Update: Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating leflunomide for relapsed or refractory CD30+ lymphoproliferative disorders has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd30 Lymphoproliferative Disorder

Drugs mentioned

• Leflunomide (Leflunomide)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder | Phase 2 | Status: COMPLETED | Results posted: 2023-12-05